Alfresa Holdings Corporation operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Alfresa Holdings with three other
companies in this sector in Japan:
Toho Holdings Company Limited
sales of 1.21 trillion Japanese Yen [US$10.71 billion]
of which 92%
was Pharmaceutical Wholesale Business),
Medipal Holdings Corporation
(3.15 trillion Japanese Yen [US$27.78 billion]
of which 67%
was Pharmaceuticals And Food Precessing Whol), and
Suzuken Co., Ltd.
(2.12 trillion Japanese Yen [US$18.75 billion]
of which 93%
was Pharmaceutical Wholesale Business).
During the year ended March of 2018, sales at
Alfresa Holdings were ¥2.60 trillion (US$22.98 billion).
increase of 2.0%
versus 2017, when the company's sales were ¥2.55 trillion.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Alfresa Holdings had sales
of ¥2.39 trillion.
Sales of Medical Treatment Related Business saw an increase
that was more than double the company's growth rate: sales were up
12.1% in 2018, from
¥30.27 billion to ¥33.93 billion.
Alfresa Holdings also saw significant increases in sales in
Wholesale Business of Self-Medication (up 3.8% to ¥259.40 billion)
Not all segments of Alfresa Holdings experienced an increase in sales in 2018:
sales of Manufacturing Pharmaceuticals, Etc. fell 0.2% to ¥32.04 billion.
(However, this segment's sales were only a very small portion of the company's overall sales).